Terms: = Uterine cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Clinical Outcome
29 results:
1. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
[TBL] [Abstract] [Full Text] [Related]
2. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
[TBL] [Abstract] [Full Text] [Related]
3. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
4. clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A; Garg S; Tchrakian N; Dhani NC; Jimenez W; Welch S; MacKay H; Ethier JL; Gilbert L; Li X; Rodriguez A; Chan L; Bowering V; Clarke B; Zhang T; King I; Downs G; Stockley T; Wang L; Udagani S; Oza AM; Lheureux S
Nat Commun; 2023 Mar; 14(1):1452. PubMed ID: 36922497
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome analysis of intramural myoma greater than 8 cm in diameter removed during caesarean section: a retrospective study.
Shi C; Chen J; Chen A
BMC Womens Health; 2023 Feb; 23(1):60. PubMed ID: 36774454
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract] [Full Text] [Related]
7. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
8. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
Choi CH; Chung JY; Kang JH; Paik ES; Lee YY; Park W; Byeon SJ; Chung EJ; Kim BG; Hewitt SM; Bae DS
Gynecol Oncol; 2020 May; 157(2):437-443. PubMed ID: 32107047
[TBL] [Abstract] [Full Text] [Related]
9. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
10. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNAs in endometrial cancers from black and white patients.
Maxwell GL; Shoji Y; Darcy K; Litzi T; Berchuck A; Hamilton CA; Conrads TP; Risinger JI
Am J Obstet Gynecol; 2015 Feb; 212(2):191.e1-10. PubMed ID: 25174797
[TBL] [Abstract] [Full Text] [Related]
12. uterine artery embolization in single symptomatic leiomyoma: do anatomical imaging criteria predict clinical presentation and long-term outcome?
Koesters C; Powerski MJ; Froeling V; Kroencke TJ; Scheurig-Muenkler C
Acta Radiol; 2014 May; 55(4):441-9. PubMed ID: 23943627
[TBL] [Abstract] [Full Text] [Related]
13. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract] [Full Text] [Related]
14. The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma.
Smith HO; Stephens ND; Qualls CR; Fligelman T; Wang T; Lin CY; Burton E; Griffith JK; Pollard JW
Mol Oncol; 2013 Feb; 7(1):41-54. PubMed ID: 22944067
[TBL] [Abstract] [Full Text] [Related]
15. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Darcy KM; Abulafia O; Hanjani P; Pearl ML; Rubin SC; Rose PG; Small L; Benbrook DM
Gynecol Oncol; 2012 Nov; 127(2):356-61. PubMed ID: 22796461
[TBL] [Abstract] [Full Text] [Related]
16. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Liao SY; Darcy KM; Randall LM; Tian C; Monk BJ; Burger RA; Fruehauf JP; Peters WA; Stock RJ; Stanbridge EJ
Gynecol Oncol; 2010 Mar; 116(3):452-8. PubMed ID: 19913895
[TBL] [Abstract] [Full Text] [Related]
18. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer.
Yuh WT; Mayr NA; Jarjoura D; Wu D; Grecula JC; Lo SS; Edwards SM; Magnotta VA; Sammet S; Zhang H; Montebello JF; Fowler J; Knopp MV; Wang JZ
Invest Radiol; 2009 Jun; 44(6):343-50. PubMed ID: 19661844
[TBL] [Abstract] [Full Text] [Related]
19. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract] [Full Text] [Related]
20. The role of relaxin in endometrial cancer.
Kamat AA; Feng S; Agoulnik IU; Kheradmand F; Bogatcheva NV; Coffey D; Sood AK; Agoulnik AI
Cancer Biol Ther; 2006 Jan; 5(1):71-7. PubMed ID: 16322684
[TBL] [Abstract] [Full Text] [Related]
[Next]
